Pharmaceutical Technology

JANUARY 11, 2023

Under the deal, Anima will receive $42m in upfront payment and be eligible for option fees and research and development milestones of up to $540m. The company will also receive further commercial milestones and tiered royalty payments on net sales of the products.

Leads 59

Leads Pharmaceutical Marketing Sales 59

Pharmaceutical Technology

FEBRUARY 22, 2023

Under the terms of the deal, Ferrer will obtain exclusive global rights for the development and commercialisation of ASN90 to treat PSP, an orphan, a tau-related disease with a high unmet medical need. The deal terms include an upfront fee along with several development, regulatory, and commercial milestone payments.

Food and Drug Administration 52

Food and Drug Administration Food Safety Medical 52

pharmaphorum

OCTOBER 18, 2022

Under the terms, Gilead is making a $60 million upfront payment to secure rights to MGD024, a bispecific in early clinical testing that was elevated into pole position in MacroGenics’ CD123xCD3 pipeline earlier this year after the biotech decided its profile was superior to former front-runner flotetuzumab , which had reached phase 2.

Sales 52

Sales Marketing Patients 52

Pharmaceutical Technology

FEBRUARY 24, 2023

Under the expanded deal terms, Capsida will take charge of capsid discovery efforts for all the programmes, along with process development and early clinical manufacturing. Capsida will get $70m in upfront payments and a potential equity investment. It will also get mid-to-high single-digit royalty payments on future product sales.

Engineering 52

Engineering Manufacturing Medicine Leads 52

Nixon Gwilt Law

MAY 26, 2023

Highlighting reimbursement options helps your customers understand the potential return on investment they can achieve by using your technology. Assessing available reimbursement will help you better understand what your customers can afford and how to talk about your fees in a way that is familiar to them.

Healthcare 119

Healthcare Healthcare Marketing Healthcare Provider 119

pharmaphorum

AUGUST 22, 2022

The EU regulator has started its review of Cidara Therapeutics’ once-weekly antifungal rezafungin, setting up a decision next year as a new option for serious, invasive infections caused by candida species. Image by GrahamColm via Wikimedia Commons.

Marketing 52

Marketing Patients FDA Sales 52

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP.

Manufacturing 52

Manufacturing Patients Leads Pharmaceutical 52

Pharmaceutical Technology

MARCH 2, 2023

” ImmunoGen will receive $15m in upfront payment from Vertex as part of the international, multi-target licence and option agreement. ” ImmunoGen will receive $15m in upfront payment from Vertex as part of the international, multi-target licence and option agreement.

Pharmaceutical 52

Pharmaceutical Medicine Sales Medical 52

Spotio

MARCH 8, 2023

” You could offer a complete solution rather than just a piece of the payment puzzle. For example, people choose your business because they want a one-stop app for all of their payment needs. On the one hand, just about every business in the US needs what you have to offer. That means you have at least 33.2

Prospecting 52

Prospecting Sales Sales process CRM 52

Nixon Gwilt Law

DECEMBER 16, 2021

What can Healthcare and Life Sciences businesses and investors anticipate for the healthcare industry in 2022? We asked our team five direct questions about innovations in healthcare, life sciences, and digital health in the coming year: What healthcare trends or opportunities are you most excited about? And they did not disappoint!

Healthcare 52

Healthcare Healthcare Food and Drug Administration Ethics 52

Clarify Health

NOVEMBER 8, 2023

Healthcare strategy and innovation leaders from Aetna, Contigo Health, and Clarify recently hosted a webinar discussion about innovations in provider network design and management to drive higher-value, more affordable, and more accessible care for members. But just for folks who don’t know me, my name is Keith Florance. Heather: Sure.

Networking 52

Networking Management Patients Physicians 52

Evolve Your Success

JUNE 6, 2023

Diversity is not just a goal; it’s a catalyst for innovation, progress, and the transformation of the medical sales industry. Welcome to another exciting episode of the Medical Sales podcast! To celebrate Pride Month, Samuel Adeyinka interviewed a remarkable guest named Trevor Boylston. Reach out to Trevor Boylston!: This episode was a joy.

Medical sales 52

Medical sales Medical Sales Sales experience 52